Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA reviews ReGen clearance at March panel: Agency's Orthopaedic and Rehabilitation Devices advisory panel will discuss the controversial 510(k) clearance of ReGen Biologics' Collagen Scaffold device, previously Menaflex, at a March 23 meeting. Last year, FDA launched an unprecedented re-assessment of its review of the knee repair device, 510(k)-cleared in December 2008, because of concerns that internal and political pressures may have hijacked the review process. The agency unearthed serious shortcomings in the integrity of the process, and FDA vowed to conduct a separate review of the Menaflex clearance to determine whether the data support 510(k) clearance, or whether the device should be up-classified to a Class III PMA device (1"The Gray Sheet" Sept. 28, 2009)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel